Evaluating 18F-LN1 PET/CT for Urothelial Carcinomas
Clinical Evaluation of 18F-LN1 PET/CT for Imaging of Nectin-4 in Urothelial Carcinomas
This study is testing a new type of PET scan to see if it can better detect bladder cancer compared to the standard scan in patients who have or might have the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06120413 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 18F-LN1 PET/CT imaging in detecting urothelial carcinoma by comparing it with the established 18F-FDG PET imaging. A total of 30 patients diagnosed with or suspected of having urothelial carcinoma will undergo PET imaging, and the results will be compared to histopathological findings from surgery or biopsy, which serve as the gold standard for diagnosis. The goal is to assess the recognition efficiency of the new imaging agent for tumor target Nectin-4.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and above who have been diagnosed with or are highly suspected of having urothelial carcinomas and have not received treatment in the past three months.
Not a fit: Patients with uncontrolled hypertension, significant comorbidities, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing urothelial carcinoma, leading to better-targeted treatments.
How similar studies have performed: While this approach is novel in the context of urothelial carcinoma, similar imaging studies have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and above * No gender difference * Patients who have been diagnosed with, or are clinically highly suspected of, urothelial carcinomas and have had no other treatment within 3 months Exclusion Criteria: * Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg * Complicated with chronic liver disease, myocardial infarction, stroke * Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception * Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
Where this trial is running
Chengdu, Sichuan
- Departments of Nuclear Medicine, Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Hao Wang, Doctor
- Email: 474556259@qq.com
- Phone: +86-18313820216
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.